Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A C/T transition at position 677 in the gene encoding methlylenetetrahydrofolate reductase (MTHFR C677T) has been reported to interact with folate intake to modulate colorectal adenoma recurrence or cancer risk.
|
18322814 |
2008 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To identify if methylene tetra-hydrofolatereductase (MTHFR) C677T polymorphisms are associated with oesophageal adenocarcinomas in a Caucasian population and to test whether folic acid and homocysteine levels are linked with cancer risk.
|
25232254 |
2014 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To explore the role of aberrant hypermethylation of cancer-related genes, such as P16, MGMT, and hMLH1, in the esophageal squamous cell carcinoma (ESCC) as well as its relation to dietary folate intake and MTHFR C677T polymorphism, we conducted a molecular epidemiologic study in China.
|
18199718 |
2008 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is a genetic factor that has been associated with many pathologies, including cancer.
|
31170928 |
2019 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two common polymorphisms (677C>T and 1298A>C) in the gene coding for MTHFR have been shown to reduce MTHFR enzyme activity and were associated with the susceptibility to different disorders, including vascular disease, neural tube defects and lymphoid malignancies.
|
15921520 |
2005 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Some examples include the alanine-to-valine substitution at codon 222 (Ala222-->Val) [DNA: C-to-T substitution at nucleo-tide 677 (677C-->T)] in methylenetetrahydrofolate reductase (NADPH) and the cofactor FAD (in relation to cardiovascular disease, migraines, and rages), the Pro187-->Ser (DNA: 609C-->T) mutation in NAD(P):quinone oxidoreductase 1 [NAD(P)H dehy-drogenase (quinone)] and FAD (in relation to cancer), the Ala44-->Gly (DNA: 131C-->G) mutation in glucose-6-phosphate 1-dehydrogenase and NADP (in relation to favism and hemolytic anemia), and the Glu487-->Lys mutation (present in one-half of Asians) in aldehyde dehydrogenase (NAD + ) and NAD (in relation to alcohol intolerance, Alzheimer disease, and cancer).
|
11916749 |
2002 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case-control studies.
|
26081619 |
2015 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the C677T and A1298C functional polymorphisms in the MTHFR gene and their associations with breast cancer risk, as well as the potential modifying effect by plasma folate status on the MTHFR-associated risk, a hospital-based case-control study was conducted on a Taiwanese population consisting of 146 histologically confirmed incident breast cancer cases and their 285 age-matched controls without a history of cancer.
|
16777985 |
2006 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two common MTHFR polymorphisms, C677T and A1298C, which lead to an altered amino acid sequence, have been associated with a decreased enzyme activity and susceptibility to cancer suggesting that these genetic variants may modulate the risk of several malignancies.
|
18781847 |
2008 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated the C677T and A1298C polymorphisms using the TaqMan allelic discrimination assay in various malignancies.
|
17156840 |
2007 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) play an essential role in both DNA synthesis and methylation and polymorphisms in the MTHFR gene, 677C>T, 1298A>C and the MTRR gene, 66A>G, are associated with several types of malignancy.
|
19035314 |
2008 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For children with malignancy, genotyping of the MTHFR C677T polymorphism is expected to be a useful tool in reducing toxicity and improving outcome in personalized MTX therapy.
|
28696419 |
2018 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The two common functional polymorphisms of MTHFR, 677 C→T and 1298 A→C, have been shown to impact various diseases, including cancer.
|
21732284 |
2011 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The two common functional polymorphisms of MTHFR, 677 C-->T and 1298 A-->C have shown to impact several diseases including cancer.
|
20516537 |
2010 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, in meta-analyses odds ratio for MTHFR c.677C>T</span> homozygotes versus noncarriers were 1.07 (95% CI: 1.01-1.12) for any cancer, 1.77 (1.17-2.68) for esophagus cancer, 1.40 (1.19-1.66) for gastric cancer and 0.85 (0.77-0.94) for colorectal cancer.
|
20473868 |
2011 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our objective was to evaluate the MTHFR C677T-A1298C polymorphisms in patients with breast cancer and in individuals with no history of cancer, to compare the levels of genetic damage and apoptosis under folic acid (FA) deficiency between patients and controls, and to assess associations with breast cancer.
|
22901194 |
2012 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Methylene tetrahydrofolate reductase C677T leads to a decrease of about 30% in its product activity and is reported to have an effect on cancer susceptibility.
|
23934457 |
2013 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analysis of polymorphisms in the MTHFR gene has revealed associations with cancer; in particular the C677T polymorphism, which has been suggested to affect folate metabolism, DNA methylation, synthesis, and repair, and to contribute to tumor promotion in the mammary gland.
|
25966173 |
2015 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer.
|
23648444 |
2014 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cancer risk may be increased in individuals with the homozygous genotype for the MTHFR 677C-->T polymorphism who have low status of methyl-related nutrients including folate.
|
14608109 |
2003 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a prospective study to evaluate the prevalence and clinical significance of four gene variations (factor V Leiden [FVL], factor II G20210A, factor XIII Val34Leu and MTHFR C677T) in cancer patients, with and without VTE.
|
12757770 |
2003 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Common methylenetetrahydrofolate reductase gene variants (MTHFR C677T and A1298C) have been described to have opposite effects on cancer patients.
|
17488658 |
2007 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two common genetic variants, C677T and A1298C, of MTHFR are associated with number of human diseases, including cancer, as well as being involved in the modulation of therapy outcome to antifolate drugs.
|
24533714 |
2014 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The methylenetetrahydrofolate reductase (MTHFR) 677 C>T and 1298 A>C polymorphisms are associated with variations in folate levels, a phenomenon linked to the development of various malignancies.
|
25510667 |
2015 |
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, more high-quality studies and that the covariates responsible for heterogeneity should be controlled to obtain a more conclusive response about the function of MTHFR C677T in cancer.
|
24744129 |
2014 |